ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

Their core work

ECRIN is a pan-European infrastructure organization that provides operational support for multinational clinical trials. They help research teams design, manage, and run clinical studies across multiple countries by handling regulatory, ethical, and data management complexities. Their core value is enabling investigators to conduct trials that span national borders — covering everything from paediatric drug development to stroke intervention and rare disease therapies. They serve as the connective tissue between hospitals, regulators, and researchers across Europe's fragmented clinical trial landscape.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), ECRIN focused on establishing research infrastructure networks, biomedicine coordination, and neuroprotection trials, while also engaging in science communication (EuroStemCell). From 2019 onward, their work shifted strongly toward data infrastructure — FAIR principles, EOSC integration, GDPR-compliant data sharing — and they responded to the pandemic with COVID-19/SARS-CoV-2 trial support. The trajectory shows a clear move from primarily running clinical trials to also building the digital and regulatory backbone that makes those trials interoperable across Europe.

ECRIN is evolving from a trial coordination service into a data-centric infrastructure provider, positioning itself at the intersection of clinical research and European open science policy.

How they like to work

ECRIN is overwhelmingly a participant rather than a leader — coordinating only 2 of 57 projects, which reflects their role as an infrastructure service provider that joins consortia to supply trial management expertise. With 865 unique partners across 60 countries, they operate as a massive hub connecting clinical researchers, hospitals, and regulators across Europe and beyond. Their consistent presence across diverse therapeutic areas (stroke, rare diseases, regenerative medicine, HIV) shows they are a horizontal service provider, not tied to any single disease area.

ECRIN has one of the broadest collaboration networks in H2020 health research, with 865 unique consortium partners spanning 60 countries. Their reach extends well beyond the EU, reflecting the global nature of clinical trial coordination.

What sets them apart

ECRIN occupies a unique niche as the only dedicated pan-European clinical trial infrastructure — they are not a university, pharma company, or CRO, but an ERIC-like network specifically built to remove barriers to multinational clinical studies. Their disease-agnostic model means they bring the same regulatory and operational expertise whether the trial involves stroke, HIV, or paediatric rare diseases. For consortium builders, ECRIN is the go-to partner when a project involves running a clinical trial across multiple EU member states and needs someone who already knows every national ethics committee and regulatory body.

Highlights from their portfolio

• PedCRIN
  One of only 2 projects ECRIN coordinated (EUR 1.5M), building a dedicated infrastructure for paediatric clinical trials — a critical gap in European research.
• CORBEL
  Large-scale biomedical research infrastructure project (EUR 727K to ECRIN) connecting multiple ESFRI landmarks, demonstrating ECRIN's central role in the European infrastructure ecosystem.
• TENSION
  Major stroke thrombectomy RCT testing treatment in extended time windows — high clinical impact trial showcasing ECRIN's ability to support complex emergency medicine studies.